exp date isn't null, but text field is
NHS Scotland Protocol for the administration of Pamidronate Infusions in paediatric Rheumatology
Pamidronate is a bisphosphonate drug (2nd generation) used to treat conditions associated with osteoporosis, multiple fractures and bone pain. Bisphosphonates bind strongly to bone mineral and interfere with bone remodelling by slowing the process of osteoclastic bone resorption and bone turnover.
Indications for use in rheumatology
* Hypophosphatasia can mimic CRMO and can be exacerbated by Bisphosphonates. Always ensure Alkaline Phosphatase (ALP) is not below normal limits for age.
Caution must be used if child has renal impairment. Pamidronate should not be given if creatinine clearance <30mL/min/1.73m2. Patients should be well hydrated pre pamidronate and not receiving aminoglycoside antibiotics.
Last reviewed: 01 May 2021
Next review: 31 May 2024
Author(s): Scottish Paediatric & Adolescent Rheumatology Network (SPARN)
Version: 1
Approved By: SPARN
Document Id: NSD610-013.02